A provision in the federal spending package would create a streamlined Medicare coverage pathway for FDA‑approved multi‑cancer early detection (MCED) tests, enabling reimbursement without prior USPSTF endorsement and setting initial reimbursement at parity with multi‑target stool DNA colorectal tests. The provision phases in eligibility and ties reimbursement timing to 2029 implementation plans. BioCentury coverage and investor notes indicate the change addresses a priority for MCED firms and could materially alter commercial economics for several players in the space. Analysts caution that coding, billing logistics, and clinical uptake will determine winners; companies that already hold FDA clearance will be best positioned to pursue Medicare reimbursement under the new language.